Iqvia Holdings(NYSE) IQV

IQVIA Holdings Inc. NYSE:IQV helps drug makers test and sell medicines. It uses data and technology to improve patient care. These tools help companies find medical cures faster.

Data, Drugs, and Decisions

• Research & Development Solutions: Provides clinical trial services and real-world research to biopharmaceutical companies; segment revenue was $2,575 million in the three-month period ended June 30, 2026.
• Commercial Solutions: Supplies data analytics, technology, and patient engagement tools; segment revenue was $1,793 million in the three-month period ended June 30, 2026.
• Laboratory Services: Manages a global network of facilities for genomic, bioanalytical, vaccine, and biomarker analyses.
• Connected Intelligence: Combines large health data sets with artificial intelligence to provide insights to medical researchers and government agencies.

Making Strategic Moves

• Recast business segments on Jan. 1, 2026, to align with an updated operating model that merges commercial and clinical offerings.
• Borrowed $650 million on March 11, 2026, to repay maturing senior notes and support general corporate purposes.
• Issued 950 million euros of senior notes on June 11, 2026, to manage outstanding debt and revolving credit facilities.
• Increased the share repurchase authorization by $2,000 million on May 7, 2026, to expand its equity buyback program.

Global Intelligence at Scale

The company operates in over 100 countries with approximately 94,000 employees. It uses privacy-enhancing technology to analyze patient data while protecting individual identities.

The Numbers for 2026

• Revenues rose 8.7% year over year to $4,368 million in the three-month period ended June 30, 2026.
• Net cash provided by operating activities reached $1,176 million during the first six months of 2026.
• Market capitalization was $32.3 billion in the second quarter of 2026, up 19.3% year over year.
• Research & Development Solutions' contracted backlog grew to $34.2 billion as of June 30, 2026.
• The company's P/E ratio was 31.4 in the second quarter of 2026.

A New Operating Model

The company has transitioned its focus toward integrated data and clinical research solutions. Its recent reorganization reflects a shift toward more streamlined, technology-driven services for the life sciences industry.